Year: 2010
Type: article
Study design: Observational Study
Abstract: BACKGROUND: The unambiguous identification of the epileptogenic tubers in individuals with tuberous sclerosis complex (TSC) can be challenging. We assessed whether magnetic source imaging (MSI) and coregistration of (18)fluorodeoxyglucose PET (FDG-PET) with MRI could improve the identification of the epileptogenic regions noninvasively in children with TSC. METHODS: In addition to standard presurgical evaluation, 28 children with intractable epilepsy from TSC referred from 2000 to 2007 had MSI and FDG-PET/MRI coregistration without extraoperative intracranial EEG. RESULTS: Based on the concordance of test results, 18 patients with TSC (64%) underwent surgical resection, with the final resection zone confirmed by intraoperative electrocorticography. Twelve patients are seizure free postoperatively (67%), with an average follow-up of 4.1 years. Younger age at surgery and shorter seizure duration were associated with postoperative seizure freedom. Conversely, older age and longer seizure duration were linked with continued seizures postoperatively or prevented surgery because of nonlateralizing or bilateral independent epileptogenic zones. Complete removal of presurgery MSI dipole clusters correlated with postoperative seizure freedom. CONCLUSIONS: Magnetic source imaging and (18)fluorodeoxyglucose PET/MRI coregistration noninvasively localized the epileptogenic zones in many children with intractable epilepsy from tuberous sclerosis complex (TSC), with 67% seizure free postoperatively. Seizure freedom after surgery correlated with younger age and shorter seizure duration. These findings support the concept that early epilepsy surgery is associated with seizure freedom in children with TSC and intractable epilepsy.
Source: Neurology
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: National Science Foundation, Epilepsy Foundation, Questcor Pharmaceuticals, Johns Hopkins University, Valeant Pharmaceuticals International, Marinus Pharmaceuticals, Eisai, H. Lundbeck A/S, National Institutes of Health, National Institute of Mental Health, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke, Janssen Pharmaceuticals
Awards: Clinical Research Program for the Partial Epilepsies, Validation of High-Throughput Screening of Candidate Antiepileptogenic Drugs, Impact of Initial Therapy and Response on Long Term Outcome in Children with CAE, Neural mechanisms of auditory feedback during speech, Pathophysiology of Developing Dysplastic Human Cortex, G607395552, Neurobiological basis of Depression as a Comorbidity in Epilepsy, Potential Surrogate Marker of Epileptogenic Cortex, Neurofibromatosis Type I as a Model for Therapeutic Neuroadaptation, The Epilepsy Phenome/ Genome Project (EPGP), The Effect of Epilepsy Surgery on Social Cognition, Epileptogenicity in the Developing Brain, Cortical spatiotemporal plasticity in humans, G9000163543
OpenAlex ID: W2117189609
